Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for genetic diseases. Its core products include Attruby/Beyonttra, an oral therapy for transthyretin amyloid cardiomyopathy, and late-stage clinical candidates targeting achondroplasia, autosomal dominant hypocalcemia, and limb girdle muscular dystrophy. BridgeBio leverages genetic insights and innovative drug platforms to address high unmet medical needs, serving patients through regulatory approvals and strategic partnerships.
This description was generated via AI from an annual report. Updated about 1 year ago.